Patents Represented by Attorney James Epperson

Find this attorney in the Justia Lawyer Directory

  • HCV NS5B inhibitors
    Patent number: 7456165
    Abstract: The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Carl P. Bergstrom, Scott W. Martin, Thomas W. Hudyma
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7456166
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: May 3, 2007
    Date of Patent: November 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam
  • Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
    Patent number: 7452876
    Abstract: The invention encompasses compounds as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: May 31, 2007
    Date of Patent: November 18, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Min Ding, Robert G. Gentles, John F. Kadow
  • Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
    Patent number: 7449586
    Abstract: The invention relates to novel processes for the preparation of small molecule antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”) and intermediates thereof.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: November 11, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Xiaojan Han, Xiang-Jun J. Jiang
  • Tetrahydrocarboline antiviral agents
    Patent number: 7449476
    Abstract: The invention encompasses a series of tetrahydrocarboline compounds of Formula I which inhibit HIV entry by attaching to the exterior viral envelop protein gp120 and interrupting the viral entry process, possibly by interfering with the cellular receptor CD4. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: November 11, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Edward H. Ruediger, Daniel H. Deon, John F. Kadow
  • HIV integrase inhibitors: cyclic pyrimidinone compounds
    Patent number: 7419969
    Abstract: The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: September 2, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Timothy P. Connolly, Yasutsugu Ueda
  • Constrained compounds as CGRP-receptor antagonists
    Patent number: 7384931
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: June 10, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang
  • Constrained compounds as CGRP-receptor antagonists
    Patent number: 7384930
    Abstract: The invention encompasses constrained bicyclic and tricyclic CGRP-receptor antagonists, methods for identifying them, pharmaceutical compositions comprising them, and methods for their use in therapy for treatment of migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: June 10, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Stephen E. Mercer, Haiquan Fang
  • Inhibitors of HCV replication
    Patent number: 7348425
    Abstract: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Grant
    Filed: February 3, 2006
    Date of Patent: March 25, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas W. Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P. Bergstrom, Piyasena Hewawasam, Scott W. Martin, Robert G. Gentles
  • HIV integrase inhibitors: cyclic pyrimidinone compounds
    Patent number: 7273859
    Abstract: The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: September 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: B. Narasimhulu Naidu
  • 2-aryl thiazole derivatives as KCNQ modulators
    Patent number: 7273866
    Abstract: Novel 2-arylthiazole derivatives of Formula I are described which are openers of KCNQ potassium channels and are useful in the treatment of disorders that are responsive to the opening of the KCNQ potassium channels, including pain and migraine
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: September 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Yong-Jin Wu, Jason M. Guernon
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7192948
    Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: March 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jacques Banville, Gilles Bouthillier, B. Narasimhulu Naidu, Roger Remillard, Michael A. Walker
  • 3-thia-4-arylquinolin-2-one derivatives
    Patent number: 7179920
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: February 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Piyasena Hewawasam, Sing-Yuen Sit
  • Aryloxyalkylamine NK-1/SSRI inhibitors
    Patent number: 7179926
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: February 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yazhong Huang, Shuanghua Hu, Andrew P. Degnan
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7176196
    Abstract: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7173022
    Abstract: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: February 6, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, John D. Matiskella, Serge Plamondon, Yasutsugu Ueda
  • Bicyclic heterocycles as HIV integrase inhibitors
    Patent number: 7157447
    Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: January 2, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Jacques Banville, Francis Beaulieu, Timothy P. Connolly, Mark R. Krystal, John D. Matiskella, Carl Ouellet, Serge Plamondon, Roger Remillard, Margaret E. Sorenson, Yasutsugu Ueda, Michael A. Walker
  • Inhibitors of HCV replication
    Patent number: 7153848
    Abstract: Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.
    Type: Grant
    Filed: July 14, 2005
    Date of Patent: December 26, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas W. Hudyma, Xiaofan Zheng, Feng He, Min Ding, Carl P. Bergstrom, Piyasena Hewawasam, Scott W. Martin, Robert G. Gentles
  • Potassium channel modulators
    Patent number: 7151180
    Abstract: This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: December 19, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Sing-Yuen Sit, John E. Starrett, Jr.
  • Sulfonamide bicyclic compounds
    Patent number: 7144894
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their uses in inhibiting ?-amyloid peptide (?-AP) production
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: December 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventor: Paul J. Gilligan